A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Clinical trial NCT05240131 · UNKNOWN
Trial details
- NCT number
- NCT05240131
- Sponsor
- Galecto Biotech AB
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-15
- Primary completion
- 2024-05-30
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.